TriangleDSP107 + Atezolizumab (NCT07235293)
DSP107 + Atezolizumab trial for Colorectal Cancer (NCT07235293). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with inoperable advanced colorectal cancer that is microsatellite-stable and/or mismatch-repair-proficient, after standard treatments. Prior fruquintinib or regorafenib is excluded.
The idea: patients are randomly assigned to intravenous DSP107 plus atezolizumab, or oral fruquintinib. DSP107 targets immune signals CD47 and 4-1BB; atezolizumab blocks PD-L1. Fruquintinib blocks blood-vessel growth signals. Researchers compare survival. Fruquintinib is taken for three weeks, followed by one week off. No more than three prior treatment lines are allowed.
This phase 2 study plans 90 patients. Kahr Bio Australia sponsors it; six US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.